JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andersen, O
Right arrow Articles by Soelberg Sørensen, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andersen, O
Right arrow Articles by Soelberg Sørensen, P
Journal of Neurology Neurosurgery and Psychiatry 2004;75:706-710
© 2004 BMJ Publishing Group Ltd


PAPER

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

O Andersen1, I Elovaara2, M Färkkilä4, H J Hansen3, S I Mellgren5, K-M Myhr6, M Sandberg-Wollheim7, P Soelberg Sørensen8 The Nordic SPMS Study Group

1 Institute of Clinical Neuroscience, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden
2 Neuroimmunology Unit, Department of Neurology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
3 Neurology Department, Århus Community Hospital, Århus, Denmark
4 Department of Neurology, Helsinki University, Helsinki, Finland
5 Department of Neurology, University Hospital of North Norway, Tromsö, Norway
6 Department of Neurology, Haukeland Hospital, Bergen, Norway
7 Department of Neurology, University Hospital, University of Lund, Lund, Sweden
8 Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Correspondence to:
Correspondence to:
Professor Oluf Andersen
Institute of Clinical Neuroscience, Neurologen-Sahlgrenska, Sahlgrenska University Hospital, SE 413 45 Göteborg, Sweden; oluf.andersen{at}neuro.gu.se

Objective: Interferon (IFN) beta has repeatedly shown benefit in multiple sclerosis (MS) in reducing the rate of relapse, the disease activity as shown with magnetic resonance imaging and, to some degree, the progression of disability; however, it is unknown how much the therapeutic response depends on the dose, the subgroup involved, and the disease stage. This multicentre, double blind, placebo controlled study explored the dose–response curve by examining the clinical benefit of low dose IFN beta-1a (Rebif®), 22 µg subcutaneously once weekly, in patients with secondary progressive MS.

Methods: A total of 371 patients with clinically definite SPMS were randomised to receive either placebo or subcutaneous IFN beta-1a, 22 µg once weekly, for 3 years. Clinical assessments were performed every 6 months. The primary outcome was time to sustained disability, as defined by time to first confirmed 1.0 point increase on the Expanded Disability Status Scale (EDSS). Secondary outcomes included a sensitive disability measure and relapse rate.

Results: Treatment had no beneficial effect on time to confirmed progression on either the EDSS (hazard ratio (HR) = 1.13; 95% confidence interval (CI) 0.82 to 1.57; p = 0.45 for 22 µg v placebo) or the Regional Functional Status Scale (HR = 0.93; 95% CI 0.68 to 1.28; p = 0.67). Other disability measures were also not significantly affected by treatment. Annual relapse rate was 0.27 with placebo and 0.25 with IFN (rate ratio = 0.90; 95% CI 0.64 to 1.27; p = 0.55). The drug was well tolerated with no new safety concerns identified. No significant gender differences were noted.

Conclusions: This patient population was less clinically active than SPMS populations studied in other trials. Treatment with low dose, IFN beta-1a (Rebif®) once weekly did not show any benefit in this study for either disability or relapse outcomes, including a subgroup with preceding relapses. These results add a point at one extreme of the dose–response spectrum of IFN beta therapy in MS, indicating that relapses in this phase may need treatment with higher doses than in the initial phases.


Keywords: secondary progressive multiple sclerosis; interferon beta; randomised controlled trial

Abbreviations: EDSS, Expanded Disability Status Scale; EU-SPMS, European Secondary Progressive Multiple Sclerosis trial; HR, hazard ratio; IFN, interferon; IM, intramuscular; KFS, Kurtzke Functional System; MRI, magnetic resonance imaging; PH, proportional hazard; RFSS, Regional Functional System Score; RRMS, relapsing–remitting multiple sclerosis; SAE, serious adverse event; SC, subcutaneous; SPMS, secondary progressive multiple sclerosis; TTP, time to progression




This article has been cited by other articles:


Home page
Mult SclerHome page
A.G. Beiske, H. Naess, J.H. Aarseth, O. Andersen, I. Elovaara, M. Farkkila, H.J. Hansen, S.I. Mellgren, M. Sandberg-Wollheim, P.S. Sorensen, et al.
Health-related quality of life in secondary progressive multiple sclerosis
Multiple Sclerosis, April 1, 2007; 13(3): 386 - 392.
[Abstract] [PDF]


Home page
NeurologyHome page
M. Sandberg-Wollheim, D. Frank, T. M. Goodwin, B. Giesser, M. Lopez-Bresnahan, M. Stam-Moraga, P. Chang, and G. S. Francis
Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
Neurology, September 27, 2005; 65(6): 802 - 806.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
S. B Patten, G. Francis, L. M Metz, M. Lopez-Bresnahan, P. Chang, and F. Curtin
The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis
Multiple Sclerosis, April 1, 2005; 11(2): 175 - 181.
[Abstract] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., September 1, 2004; 9(5): e5 - e5.
[Full Text] [PDF]


Home page
BMJHome page
H. Marcovitch
What's new this month in BMJ Journals
BMJ, May 8, 2004; 328(7448): 1098 - 1098.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.